Perspectives

Kelvin Tan

At Jazz Pharmaceuticals, we’re committed to developing life-changing medicines for people affected by serious diseases for which current therapies are lacking. This begins with talking to those living with disease and reflecting their needs in our R&D priorities and throughout all stages of our drug development process as we pursue novel, meaningful medicines that advance patient care.

Bruce Cozadd

Bruce Cozadd, our Chief Executive Officer, looks back on Jazz’s major achievements of 2021 amid ongoing challenges of the pandemic, reflecting on the significant strides made for patient populations, and reinstating Jazz’s continued commitment to developing breakthrough therapeutics as we kick off 2022.


In November, our Jazz Association of Women Supporters employee-led Affinity Forum hosted an exciting virtual event for our members to discuss allyship for women, and the various actions we can all take to be an ally to advocate for women and their career development.

Bruce Cozadd

Recently, Bruce Cozadd, our Chairman and Chief Executive Officer, sat down with Wynton Marsalis, Artistic Director of Jazz at Lincoln Center, for a fireside chat where they explored the principles that jazz music and pluralism share, and how to apply them to leadership and citizenry. Bruce reflects on the conversation and how these principles have been brought to life at Jazz Pharmaceuticals.

Ryan Bovia

At Jazz, National Epilepsy Awareness Month serves as a crucial moment to recognize the importance of raising awareness for patients with severe forms of epilepsy, and how we at Jazz work to continuously provide support for patients and caregivers.

Kim Sablich

We believe all people, particularly those who live with complex conditions, deserve new and better therapeutic options, and for the approximately 37,000 adult patients who have been diagnosed with idiopathic hypersomnia and are actively seeking care, this launch is a sign of hope the population has yet to see.